6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氢咪唑并[2,1-B]-噻唑
| 中文名称 | 6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氢咪唑并[2,1-B]-噻唑 |
|---|---|
| 中文同义词 | 6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氢咪唑并[2,1-B]-噻唑 |
| 英文名称 | 6-(4-FLUOROPHENYL)-2,3-DIHYDRO-5-(4-PYRIDINYL)IMIDAZO[2,1-B]THIAZOLE DIHYDROCHLORIDE |
| 英文同义词 | 6-(4-FLUOROPHENYL)-5-(4-PYRIDYL)-2,3-DIHYDROIMIDAZO[2,1-B]-THIAZOLE;6-(4-FLUOROPHENYL)-2,3-DIHYDRO-5-(4-PRIDYL)IMIDAZO-[2,1,B]-THAIZOLE;6-(4-FLUOROPHENYL)-2,3-DIHYDRO-5-(4-PYRIDINYL)IMIDAZO[2,1-B]THIAZOLE DIHYDROCHLORIDE;6-(4-FLUOROPHENYL)-2,3-DIHYDRO-5-(4-PYRIDYL)IMIDAZO[2,1-B]THIAZOLE;SKF-86002;SKF 86002 DIHYDROCHLORIDE;6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole;4-(4-Pyridyl)-5-(4-fluorophenyl)-2,3-dihydro-1-thia-3a,6-diazapentalene |
| CAS号 | 72873-74-6 |
| 分子式 | C16H12FN3S |
| 分子量 | 297.35 |
| EINECS号 | |
| 相关类别 | 抑制剂;小分子抑制剂;小分子抑制剂，天然产物;Inhibitors;Protein Kinase |
| Mol文件 | 72873-74-6.mol |
| 结构式 | ![6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氢咪唑并[2,1-B]-噻唑 结构式](CAS/GIF/72873-74-6.gif) |
6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氢咪唑并[2,1-B]-噻唑 性质
| 熔点 | 189-190 °C(lit.) |
|---|---|
| 沸点 | 476.1±55.0 °C(Predicted) |
| 密度 | 1.39±0.1 g/cm3(Predicted) |
| 储存条件 | Keep in dark place,Sealed in dry,2-8°C |
| 溶解度 | DMSO：可溶9 mg/mL |
| 形态 | 固体 |
| 酸度系数(pKa) | 4.36±0.10(Predicted) |
| 颜色 | 米白色 |
| InChIKey | YOELZIQOLWZLQC-UHFFFAOYSA-N |
SKF-86002 是一种具有口服活性的 p38 MAPK 抑制剂，具有抗炎、抗关节炎和镇痛活性。SKF-86002 能抑制脂氧合酶和环氧合酶介导的花生四烯酸代谢。
SKF-86002 (10 μM; 1 hour) inhibits apoptosis induced by stress stimulation with UV irradiation (UV).
SKF-86002 does not inhibit UV-induced apoptosis in undifferentiated HL-60 cells.
SKF-86002 (10 μM; 72 hours) prevent IL-4-induced monocyte or U937 cell CD23 surface expression and protein formation with no effect on CD23 mRNA levels.
Western Blot Analysis
| Cell Line: | U937 cells |
| Concentration: | 10 μM |
| Incubation Time: | 72 hours |
| Result: | Significantly reduced CD23 levels on IL-4-treated U937 cells. |
SKF-86002 (10-90 mg/kg; p.o.; daily; for 22 days) has antiarthritic activity.
| Animal Model: | Lewis rats, with adjuvant-induced arthritis (AA) |
| Dosage: | 10 mg/kg, 30 mg/kg, 90 mg/kg |
| Administration: | Oral administration, daily, for 22 days |
| Result: | Significantly decreased hindleg volumes after injection of adjuvant. |
| 提供商 | 语言 |
|---|---|
|
英文
|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-12511 | 6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氢咪唑并[2,1-B]-噻唑 SKF-86002 | 72873-74-6 | 2mg | 400元 |
| 2024/01/25 | HY-12511 | 6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氢咪唑并[2,1-B]-噻唑 SKF-86002 | 72873-74-6 | 5 mg | 810元 |